ArticleJHEP reports : innovation in hepatology2023
Blueprint to hepatitis B elimination in China: A modelling analysis of clinical strategies.
Article in JHEP reports : innovation in hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Forecasting monthly hepatitis B cases in China: a nationwide comparative study based on surveillance data.BMC public health · 2026Article
- Feasibility of eliminating adult hepatitis B in Guangdong by 2030: A modeling study.Infectious Disease Modelling · 2026Article
- Besifovir: a viable option for long-term disease control in chronic hepatitis B: Editorial on "Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial".Clinical and molecular hepatology · 2026Article
- Critical analysis of the liver cancer policies and programs in China: implications for international liver cancer control.Global health research and policy · 2025Article
- Dynamic predicting hepatitis B surface antigen decline rate during treatment for patients with chronic hepatitis B.Infectious Disease Modelling · 2025Article
- Epidemiology, Achievements, and Challenges in the Elimination of Hepatitis B in China.Journal of clinical and translational hepatology · 2025Review
- Modeling hepatitis B-related deaths in China to achieve the WHO's impact target.Infectious Disease Modelling · 2025Article
- Expanding treatment indications in chronic hepatitis B: Should we treat all patients?Hepatology international · 2025Review
- [Recent advances in epidemiology, prevention and treatment of hepatitis B in China].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Correlation Between Clinical Indicators and Liver Pathology in Children with Chronic Hepatitis B.Biomedicines · 2024Article
- Correspondence to editorial on "Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study".Clinical and molecular hepatology · 2024Article
- Outcome of bariatric surgery in patients with unexpected liver cirrhosis: A multicenter study from China.Liver research (Beijing, China) · 2024Article
- Expert Consensus on the Prevention and Treatment of Chronic Hepatitis B in Children.Infectious diseases & immunity · 2024Article
- [Research progress on clinical antiviral treatment of chronic hepatitis B in children].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Article
- The History of Controlling and Treating Infectious Diseases in Ancient China.Current medical science · 2024Review
- Antiviral treatment standards for hepatitis B: An urgent need for expansion.World journal of gastroenterology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Background & Aims: Globally, one-third of individuals infected with HBV live in China. Eliminating HBV in China would therefore be paramount in achieving the World Health Organization's (WHO's) targets of viral hepatitis elimination as a worldwide public health threat. Methods: We constructed a dynamic HBV transmission model in China, structured by age and sex. We calibrated the model by HBsAg prevalence, acute HBV incidence, and nationally reported HBV-related cancer mortality. We investigated seven intervention scenarios (A-G) based on assumptions in diagnostic, linkage-to-care, and treatment coverages in achieving the WHO's HBV elimination goals. Results: With the Conclusions: Eliminating HBV will require interventional strategies to improve diagnostic, linkage-to-care, and treatment coverages. Developing novel therapies will be crucial in further reducing HBV-related mortality and removing HBV as a public health threat. Impact and Implications: This study explores the key developments and optimal intervention strategies needed to achieve WHO hepatitis B elimination targets by 2030 in China. It highlights that China can realise the HBV elimination targets in the incidence by 2025, and by upscaling diagnostic, linkage-to-care, and treatment coverages, up to 2 million lives could potentially be saved from HBV-related deaths.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.